Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

MBDA Briefing at Williams Foundation Seminar, April 11, 2019

112 views

Published on

This briefing by Chris Stevens from MBDA highlights the UK approach to sovereignty with regard to its weapons enterprise.
It was presented at the Williams Foundation Seminar in Canberra, Australia, April 11, 2019

Published in: News & Politics
  • Be the first to comment

  • Be the first to like this

MBDA Briefing at Williams Foundation Seminar, April 11, 2019

  1. 1. The UK Weapons Portfolio Successfully providing Freedom of Action and Operational Advantage” Chris Stevens UK SBD - Head of Air Domain
  2. 2. This document and the information contained herein is proprietary information of MBDA and shall not be disclosed or reproduced without the prior authorisation of MBDA. © MBDA UK Ltd 2019. - Reference :Page : The UK Complex Weapons Community 2 Supply Chain Partners Weapons Evaluation & Capability Assurance (WECA) Weapons Operating Centre (WOC) Joint Portfolio Management Supply Chain OFFICIAL OFFICIAL
  3. 3. This document and the information contained herein is proprietary information of MBDA and shall not be disclosed or reproduced without the prior authorisation of MBDA. © MBDA UK Ltd 2019. - Reference :Page : How did it come about? 3 Defence Industrial Strategy 2005 Retain the capability within UK industry to design, develop, assemble and upgrade Complex Weapons ensuring Operational Advantage and Freedom of Action Needed a solution which would: •  Deliver CW military capability for UK Armed Forces •  Provide savings to the UK MOD and UK taxpayer •  Deliver flexibility and agility against changing requirements •  Deliver Freedom of Action and Operational Advantage for the UK •  Secure high tech UK jobs in the CW Sector OFFICIAL OFFICIAL
  4. 4. This document and the information contained herein is proprietary information of MBDA and shall not be disclosed or reproduced without the prior authorisation of MBDA. © MBDA UK Ltd 2019. - Reference :Page : Routemap OFFICIAL4 OFFICIAL
  5. 5. This document and the information contained herein is proprietary information of MBDA and shall not be disclosed or reproduced without the prior authorisation of MBDA. © MBDA UK Ltd 2019. - Reference :Page : Common Objectives 5 MOD require: •  Current & future Military Capability •  Operational Advantage •  Freedom of Action •  Value for Money MBDA desires: •  Sustainable & profitable business •  To be supplier of choice to MoD for Complex Weapons Jointly achieved by: •  Adopting a partnering relationship and a collaborative approach to the long-term delivery of UK CW Military Capability •  Working together to increase export of UK developed weapons to provide benefit to both parties OFFICIAL OFFICIAL
  6. 6. This document and the information contained herein is proprietary information of MBDA and shall not be disclosed or reproduced without the prior authorisation of MBDA. © MBDA UK Ltd 2019. - Reference :Page : Problem and solution summary 6 Budget Military Capability Sovereignty (Freedom of Action) •  Unstable and unaffordable programme •  Stable and affordable programme Pre and Post Portfolio: •  Legacy of capability overlaps and gaps based on platform-centric stovepipe procurement •  Fewer capability overlaps and gaps, families of weapons •  Low degree of sovereignty based on open competition and MOTS procurement •  High degree of sovereignty based on single- source procurement from UK supplier base OFFICIAL OFFICIAL
  7. 7. This document and the information contained herein is proprietary information of MBDA and shall not be disclosed or reproduced without the prior authorisation of MBDA. © MBDA UK Ltd 2019. - Reference :Page : Commonality, Modularity, Re-use 7 Greater capability coverage and flexibility delivered through a long-term vision towards common and modular CW families OFFICIAL OFFICIAL
  8. 8. This document and the information contained herein is proprietary information of MBDA and shall not be disclosed or reproduced without the prior authorisation of MBDA. © MBDA UK Ltd 2019. - Reference :Page : Commonality, Modularity, Re-use Example CAMM 8 OFFICIAL OFFICIAL
  9. 9. This document and the information contained herein is proprietary information of MBDA and shall not be disclosed or reproduced without the prior authorisation of MBDA. © MBDA UK Ltd 2019. - Reference :Page : Commonality, Modularity, Re-use CAMM Family 9 ASRAAM Sea CEPTOR Land CEPTOR
  10. 10. This document and the information contained herein is proprietary information of MBDA and shall not be disclosed or reproduced without the prior authorisation of MBDA. © MBDA UK Ltd 2019. - Reference :Page : The VfM Argument 10 2010 Deloitte Analysis Key Principle: procuring Complex Weapons through a portfolio approach with MBDA delivers better Value for Money than procurement of equivalent capability through Open Competition 2015 ‘Sector Investment Appraisal’ reconfirmed Greater than £1Bn better VfM than Open Competition (10-Years from 2015) “The (PMA) arrangement presents a £1.2bn cost-capability net benefit over competitive procurement within 10 years” [Deloitte] OFFICIAL OFFICIAL
  11. 11. This document and the information contained herein is proprietary information of MBDA and shall not be disclosed or reproduced without the prior authorisation of MBDA. © MBDA UK Ltd 2019. - Reference :Page : Benefit Categories 11 OFFICIAL OFFICIAL
  12. 12. This document and the information contained herein is proprietary information of MBDA and shall not be disclosed or reproduced without the prior authorisation of MBDA. © MBDA UK Ltd 2019. - Reference :Page : Delivering Capability 12 OFFICIAL OFFICIAL
  13. 13. This document and the information contained herein is proprietary information of MBDA and shall not be disclosed or reproduced without the prior authorisation of MBDA. © MBDA UK Ltd 2019. - Reference :Page : Air Domain Leading the way 13 OFFICIAL OFFICIAL
  14. 14. This document and the information contained herein is proprietary information of MBDA and shall not be disclosed or reproduced without the prior authorisation of MBDA. © MBDA UK Ltd 2019. - Reference :Page : 14 QUESTIONS?

×